Two recent studies are particularly relevant in this regard: The first study (Bold et al., 2022) showed that APPsα (the proteolytic cleavage product of APP along the nonamyloidogenic pathway, i.e., the one not producing Aβ) rescued abnormally low spine density in tauopathy model mice, even when applied at nanomolar concentrations. This evidence concerns the gene APP and tauopathy.